Serina Therapeutics Inc. is a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases. Serina Therapeutics Inc., formerly known as AgeX Therapeutics Inc., is based in HUNTSVILLE, Ala.
| Revenue (Most Recent Fiscal Year) | $0.13M |
| Net Income (Most Recent Fiscal Year) | $-19.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.70 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -16358.46% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -416.40% |
| Return on Assets (Trailing 12 Months) | -132.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.65 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.16 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.74 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.89 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 25.40M |
| Free Float | 20.90M |
| Market Capitalization | $69.34M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 1.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.50% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |